www.fdanews.com/articles/175006-alks-asthma-prevention-candidate-misses-primary-endpoint
ALK’s Asthma Prevention Candidate Misses Primary Endpoint
January 22, 2016
In a five-year study, ALK-Abello’s Grazax asthma prevention candidate failed to meet its primary endpoint of time to first diagnosis of reversible impairment of lung function.
Nevertheless, the company says it is encouraged to see a clinically meaningful treatment effect on asthma symptoms.